Maa: Kanada
Kieli: englanti
Lähde: Health Canada
FAMOTIDINE
MERCK CANADA INC
A02BA03
FAMOTIDINE
10MG
TABLET
FAMOTIDINE 10MG
ORAL
30
OTC
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0118722003; AHFS:
APPROVED
2005-07-29
PRODUCT MONOGRAPH PEPCID AC ® (famotidine tablets, Frosst Std.) Film Coated Tablets 10 mg and PEPCID AC ® (famotidine chewable tablets) Chewable Tablets 10 mg and PEPCID AC ® (famotidine tablets, Frosst Std.) Gelcaps 10 mg THERAPEUTIC CLASSIFICATION Histamine H 2 Receptor Antagonist Distributed by: Johnson & Johnson•MERCK Consumer Pharmaceuticals Guelph, Canada, N1K 1A5 Manufacturer: MERCK FROSST CANADA LTD. KIRKLAND, QUEBEC, CANADA PEPCID ® AC is a Trademark of Merck & Co., Inc., Used under license. Date of Preparation: August 4, 2005 Date of Revision: Control Number: 100128 2 PRODUCT MONOGRAPH PEPCID AC ® (famotidine tablets, Frosst Std.) Tablets 10 mg and PEPCID AC ® (famotidine chewable tablets) Chewable Tablets 10 mg and PEPCID AC ® (famotidine tablets, Frosst Std) Gelcaps 10 mg THERAPEUTIC CLASSIFICATION Histamine H 2 Receptor Antagonist CLINICAL PHARMACOLOGY PEPCID AC ® (famotidine) is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of PEPCID AC ® is inhibition of gastric juice secretion. PEPCID AC ® reduces the acid and pepsin content, as well as the volume, of basal, nocturnal, and stimulated gastric secretion. INDICATIONS AND CLINICAL USE PEPCID AC ® (famotidine) is indicated in the treatment of the following conditions where a controlled reduction of gastric secretion is required, such as acid indigestion, heartburn, sour or upset stomach. PEPCID AC ® is also indicated for the prevention of these symptoms when associated with the consumption of food and/or beverage including nocturnal symptoms associated with the evening meal and expected to cause sleep disturbance. PEPCID AC ® is a Trademark of Merck & Co., Inc. Used under license. 3 CONTRAINDICATIONS Hypersensitivity to any component of this medication. Cross sensitivity in this class of compounds has been observed. Therefore, PEPCID® AC should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists. PRECAUTIONS General In clinical Lue koko asiakirja